Embryonic stem cells and repair of lung injury.
Embryonic stem cells and repair of lung injury.
复制标题
胚胎干细胞与肺损伤修复。
DOI：
10.1038/mt.2010.8
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
Finck,Christine
中科院分区：
文献类型：
--
作者：
Weiss,DanielJ;Finck,Christine
肺部疾病的细胞治疗方法继续快速发展。早期的研究表明，来源于成人骨髓或其他成人组织的干细胞或祖细胞可以移植为肺上皮细胞，其数量足以实现肺结构修复或替换囊性纤维化、肺气肿和其他病症中有缺陷或受损的气道或肺泡上皮细胞。1然而，现在人们认识到，结构植入通常是一种罕见的发生不确定的意义，虽然最近的研究表明，成人或胎盘来源的细胞的植入可能会被诱导发生在更高的水平。2，3在这一期的《分子治疗》杂志中，Wang及其同事的一项研究4表明，在实验诱导的肺损伤小鼠中，人胚胎干细胞（hESC）在培养中分化成具有II型肺泡上皮细胞（肺表面活性物质产生细胞）表型标志物的细胞，经气管内滴注hESC可提高小鼠的存活率，并改善肺部炎症和纤维化。这是第一个可用的信息表明，从胚胎干细胞衍生的细胞可以在肺损伤中具有有益的作用，它提供了一个平台，在各种肺部疾病的胚胎干细胞的潜在治疗用途。
Cell therapy approaches for lung diseases continue to evolve at a rapid pace. Early studies suggested that stem or progenitor cells derived from adult bone marrow or other adult tissues might engraft as lung epithelium in numbers sufficient to effect structural lung repair or replacement of defective or damaged airway or alveolar epithelial cells in cystic fibrosis, emphysema, and other conditions. 1 However, it is now recognized that structural engraftment is generally a rare occurrence of uncertain significance, although recent studies suggest that engraftment of adult or placental origin cells might be induced to occur at higher levels. 2, 3 In this issue of Molecular Therapy, a study by Wang and colleagues4 shows that intratracheal instillation of human embryonic stem cells (hESCs), previously differentiated in culture into cells with phenotypic markers of type II alveolar epithelial cells—the surfactant-producing cells of the lungs—improved survival and ameliorated lung inflammation and fibrosis in mice with experimentally induced lung injury. This is the first available information demonstrating that cells derived from ESCs can have beneficial effects in lung injury, and it provides a platform for potential therapeutic use of ESCs in a variety of lung diseases.